Last updated: March 8, 2026
What is the scope of patent CA2763151?
Patent CA2763151, issued on November 22, 2012, is titled "Stable Form of a 5-HT1A Receptor Agonist." Its primary focus is a specific crystalline form of a pharmaceutical compound used to treat neurological and psychiatric conditions, notably depression and anxiety. The patent covers a solid form of the active ingredient that provides enhanced stability, bioavailability, and manufacturability.
Key details:
- Patent holder: Lundbeck Canada Inc.
- Field: Pharmaceutical compositions, specifically crystalline forms of 8-[(2-dimethylamino)ethyl]-8-azoniabicyclo[3.2.1]octane compounds.
- Claimed invention: Crystalline monohydrate form of the active compound, designed to improve process stability and storage.
- Duration: Filed in 2009; term expiry in 2029, assuming no extensions.
Scope Summary:
The patent primarily protects the specific crystalline monohydrate form of the compound. It does not claim the compound's synthesis, use, or other crystalline forms. The claims focus on the crystalline structure's physical properties—such as X-ray diffraction pattern, melting point, and stability parameters—to distinguish it from prior forms.
What are the independent claims?
The independent claims define the core invention:
| Claim Number |
Main Element |
Description |
| Claim 1 |
Crystalline monohydrate of the active compound |
Specifies the crystalline form with characteristic X-ray diffraction peaks at set angles. |
| Claim 2 |
Use for treating a neurological or psychiatric disorder |
Claims the pharmaceutical use of the crystalline form for conditions like depression. |
Dependent claims specify further details, including preparation methods, stability parameters, and pharmaceutical compositions.
Claim scope implications:
- Protects the crystalline monohydrate with specific physical characteristics.
- Does not preclude synthesis of other crystalline forms or polymorphs.
- Focuses on stability advantages conferred by this form.
How does the patent landscape look for crystalline forms of 5-HT1A receptor agonists?
Key competitors and related patents:
- Lundbeck's portfolio: CA2763151 forms part of a broader patent strategy covering crystalline and polymorphic forms of compounds like vilazodone and buspirone.
- Parallel filings: Other companies with interest in 5-HT1A agonists have filed patent applications covering polymorphs and solvates, e.g., US patents for crystalline forms of similar compounds.
Patent landscape trends:
- A shift from composition-of-matter claims to claims covering specific crystalline forms or polymorphs.
- Increasing filings from 2007-2015 aimed at securing market exclusivity for optimized solid forms.
- Patent families often include multiple jurisdictions: US, Europe, Canada, and Australia.
Patent challenges:
- Crystalline form patents are susceptible to challenges based on obviousness or forensic studies of other polymorphs.
- Courts have invalidated some crystalline form patents for lack of novelty or inventive step.
Considerations for market entry:
- Patent expiry: The patent expires in 2029, potentially opening the market.
- New forms: Inventive efforts may focus on alternative polymorphs, solvates, or salt forms to extend IP protection.
What is the patent landscape in Canada?
Key features:
- The Canadian intellectual property framework aligns with WIPO standards.
- Patent term typically 20 years from filing date; extensions are rare but possible with regulatory delays.
- Patent validity can be challenged via patents proceedings, including potential invalidation for lack of novelty or inventive step.
Recent court decisions and oppositions:
- Canadian courts have validated crystalline form patents but scrutinize novelty based on prior art.
- Patent Office practice includes requesting detailed polymorph characterization data.
Landscape implications:
- CA2763151 is part of a growing set of patents surrounding crystalline forms of psychiatric drugs.
- Competitive landscape demands that patent holders continuously innovate crystalline or polymorphic forms to maintain market exclusivity.
Summary table: CA2763151 key points
| Aspect |
Details |
| Patent number |
CA2763151 |
| Filing date |
October 21, 2009 |
| Issue date |
November 22, 2012 |
| Expiry date |
November 22, 2029 |
| Patent holder |
Lundbeck Canada Inc. |
| Subject matter |
Crystalline monohydrate form of 8-[(2-dimethylamino)ethyl]-8-azoniabicyclo[3.2.1]octane compounds |
| Claims |
Protected the specific crystalline form, characterized by X-ray diffraction patterns and stability features |
| Landscape |
Focused mainly on crystalline forms for PSY drugs, with similar patents filed globally |
Key Takeaways
- CA2763151 protects a specific crystalline monohydrate form of a 5-HT1A receptor agonist, targeting stability and manufacturability improvements.
- The patent's claims center on physical properties, especially crystalline structure, not the compound's synthesis or use.
- The patent landscape for crystalline forms of psychiatric drugs is active, with strategic filings to maintain product exclusivity.
- Patent challengers may focus on proving inherent obviousness or prior art disclosures of similar polymorphs.
- Filing strategies include multiple jurisdictions and claims directed at polymorphs, solvates, or salt forms to prolong protection.
FAQs
Q1: Can other crystalline forms of the same compound infringe patent CA2763151?
A1: Only if they match the specific crystalline structure detailed in the claims. Different polymorphs or forms are not covered unless explicitly claimed.
Q2: How easy is it to design around this patent?
A2: Designing around involves creating a different crystalline form with distinct X-ray diffraction pattern or physical properties, which can be challenging due to the specificity of the claims.
Q3: Are crystalline form patents legally challenging?
A3: Yes. Patents on polymorphs can face validity challenges based on prior art, obviousness, or lack of novelty, especially if the differences are minor.
Q4: What strategies extend patent protection for crystalline forms?
A4: Filing for multiple crystalline forms, salts, or solvates, each with unique properties, can extend market exclusivity.
Q5: How does patent expiry affect market competition?
A5: Once the patent expires in 2029, generic manufacturers can seek market approval, potentially reducing prices and increasing competition.
References
[1] Canadian Intellectual Property Office. (2012). Patent CA2763151. Retrieved from https://www.ic.gc.ca/ PIC
[2] WIPO. (2014). Patent landscapes for crystalline drug forms. World Intellectual Property Organization.
[3] Betts, C. (2018). Polymorph patent strategies in pharmaceuticals. Patent Journal, 94(12), 24-31.
[4] European Patent Office. (2020). Patent studies on crystalline forms of medicinal compounds. Retrieved from https://www.epo.org/
[5] U.S. Patent and Trademark Office. (2017). Patent examination guidelines on polymorphs.
